沈琳 主任医师、教授，北京学者

沈琳，主任医师、教授、博士生导师。历任北京大学肿瘤医院副院长、北京市肿瘤防治研究所副所长。现任消化肿瘤内科主任、I期临床试验病区主任，北京市政协委员。担任中国抗癌协会肿瘤药物临床研究专业委员会首届主任委员、中国抗癌协会肿瘤精准治疗专业委员会主任委员、中国临床肿瘤学会临床研究专家委员会主任委员、中国女医师协会临床肿瘤专业委员主任委员等多个重要学术职务。享受国务院政府特殊津贴，获全国优秀科技工作者、全国三八红旗手荣誉称号，入选北京学者、北京市突出贡献专家。获国家科技进步二等奖、教育部科技进步一等奖、中华医学科技奖一等奖、中国抗癌协会科技奖一等奖、华夏医学科技奖一等奖及二等奖等多项奖项。

主要研究方向：

沈琳教授长期从事消化道肿瘤精准治疗，抗肿瘤新药临床与转化研究。

主要研究成果包括：

带领团队建立消化道肿瘤临床与转化研究体系，并入选2022年中国科协“科创中国”先导技术榜。牵头众多抗肿瘤新药临床研究，推动抗肿瘤新药获批上市。以第一或责任作者在Nature, BMJ, Nature Medicine, JCO等权威期刊发表SCI论文近200篇，获国家专利10项。撰写40余部国际国内胃肠道肿瘤诊疗规范。获国家科技进步二等奖、教育部科技进步一等奖、中华医学科技奖一等奖、中国抗癌协会科技奖一等奖、华夏医学科技奖一等奖及二等奖等多项奖项。

承担课题

国家重点研发计划慢病专项首席科学家，承担国家重点研发计划、国家自然科学基金重大研究计划、国家自然科学基金面上项目、国家自然科学基金面上项目、科技重大专项重大新药创制项目、973计划、863计划、北京市自然科学基金重点项目、首都市民健康项目培育项目等多项课题，并取得较大成果。

发表的代表性论文(第一#或责任作者*)

1. Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, Lee B, Riemer J, Day C, Yen R, Cui Y, Wang Y, Wang Y, Zhang W, Easwaran H, Hulbert A, Kim K, Juergens R, Yang S, Battafarano R, Bush E, Broderick S, Cattaneo S, Brahmer J, Rudin C, Wrangle J, Mei Y, Kim Y J, Zhang B, Wang K, Forde P, Margolick J, Nelkin B, Zahnow C, Pardoll D, Housseau F, Baylin S, Shen L*, Brock M. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284-290. IF：42.778

2. Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L*. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022 Apr 19;377:e068714. IF：105.7

3. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L*. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nature Medicine. 2022 Jun;28(6):1189-1198. IF：82.9

4. Shen L#*, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. IF：45.3

5. Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, Wang Y, Zhou J, Qi C, Gong J, Wang X, Li J, Tang L, Shen L*. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021 Mar 1; 39(7):748-756. IF：44.544

6. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L*, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. IF：41.316

7. Zhao S, Lv C, Gong J, Wenfeng F, Hu X, Ba Y, Xiaoyuan C, Zhimin Y, Shen L*, Zhang L. Chinese Phase 1 Oncology trial Consortium. Challenges in anticancer drug R&D in China. Lancet Oncol. 2019 Feb;20(2):183-186. IF：35.386

8. Shen L#, Shan YS, Hu HM, Price T, Sirohi B, Yeh K, Yang Y, Sano T, Yang H, Zhang X, Park S, Fujii M, Kang Y, Chen L. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535-e547. IF：25.117

9. Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, Chen Z, Zhang J, Hu Y, Yuan J, Zhao X, Li Y, Gong J, Dong B, Zhang X, Li J, Shen L*. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nature Communications. (2022) 13:4851. IF：16.6

10. Zhang C, Chong X, Jiang F, Gao J, Chen Y, Jia K, Fan M, Liu X, An J, Li J, Zhang X, Shen L*. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. Journal of Extracellular Vesicles. 2022 Apr;11(4):e12209. IF：25.841